Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.
about
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical StudiesTreatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.B cells and progressive multifocal leukoencephalopathy: search for the missing linkInfluence of the Gut Microbiome on Autoimmunity in the Central Nervous System.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.A lifetime aging study of human CD19 transgenic mice.MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19.B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
P2860
Q28067334-675B8995-3A0A-425D-82AB-D8B606E473EBQ36727762-291E2499-A26B-448F-98F7-66974E23ADBCQ38515349-A6998C8A-C379-452D-BC85-9A684C709138Q38772593-028E3382-404A-44FE-93AF-156F8B44AC93Q38837294-8A2BFCA3-C4D4-440F-948F-8717E9E4F439Q40110864-CEDE4A59-BE5F-4DFA-9BD9-693385011B26Q46059217-9EB5C52E-4820-451E-A69F-3C0073B31542Q50214974-2A2043B9-2ABC-4D99-8F82-1837A03F34F7Q53264199-2B630228-2100-4BA0-9411-088EC206E332Q55283579-449ADD7D-4404-4DC1-AA14-24D0A5A1BDB6Q58555322-20A16D58-E821-4FD5-85CF-6A53E4231653
P2860
Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Single dose of glycoengineered ...... ipheral regulatory mechanisms.
@ast
Single dose of glycoengineered ...... ipheral regulatory mechanisms.
@en
type
label
Single dose of glycoengineered ...... ipheral regulatory mechanisms.
@ast
Single dose of glycoengineered ...... ipheral regulatory mechanisms.
@en
prefLabel
Single dose of glycoengineered ...... ipheral regulatory mechanisms.
@ast
Single dose of glycoengineered ...... ipheral regulatory mechanisms.
@en
P2093
P2860
P356
P1476
Single dose of glycoengineered ...... ipheral regulatory mechanisms.
@en
P2093
Anouk Meeuwissen
Laura Carter
Monica Blazek
Nancy L Monson
Ronald Herbst
Xiangmei Kong
P2860
P304
P356
10.4049/JIMMUNOL.1401478
P407
P577
2014-10-03T00:00:00Z